Nautilus Biotechnology Inc (NAS:NAUT)

Q2 2026 Nautilus Biotechnology Inc Earnings Call Transcript

Jul 28, 2026 / 12:30 PM GMT

Release Date Price: $1.2 (-27.71%)

Transcript 10-Q8-K

Key Points

Positve

Nautilus Biotechnology Inc (NAUT) has shifted a significant share of R&D resources to its proteoform application, which has shown strong customer enthusiasm and represents a substantial commercial opportunity.
The company has recognized its first revenue from collaborations with Baylor College and the Michael J. Fox Foundation, indicating initial commercial traction.
Nautilus Biotechnology Inc (NAUT) has a cash runway extending into the first quarter of 2028, providing financial stability for ongoing development.
The proteoform assays offer unique insights at a single molecule resolution, which existing methods cannot match, providing a competitive advantage.
The company is expanding its proteoform portfolio rapidly, with plans to introduce new assays at a cadence measured in months, aiming for roughly 20 assays by mid-2028.

Negative

The broad-scale proteome application is behind schedule, with the current assay configuration not meeting the performance needed for a 2027 launch.
Nautilus Biotechnology Inc (NAUT) reported a net loss of $14.5 million for the second quarter of 2026, indicating ongoing financial challenges.
The company has a small sales team, which may limit its ability to rapidly scale commercial operations.
Revenue for the full year is expected to be approximately $0.5 million, indicating limited immediate financial returns.
There is a need for additional fundraising between now and mid-2027 to support proteoform expansion and broader market development, which could dilute existing shareholders.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NAUT.OQ - Nautilus Biotechnology Inc
Q2 2026 Nautilus Biotechnology Inc Earnings Call
Jul 28, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to the Nautilus and Biotechnology Second Quarter 2026 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question-and-answer session. To ask a question during the session, you'll need to press *11 on your telephone. You'll then hear an automated message advising your hand is raised. To withdraw your question, please press *11 again. Please be advised today's conference is being recorded. I would now like to turn the conference over to your speaker today, Chi Yanni with Gil Martin Group. Please go ahead.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.